Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension

相关文章推荐

乖乖的小熊猫 · python modbus RTU-CSDN博客· 2 年前 ·

朝气蓬勃的豆浆 · Hive学习之路（二十一）Hive ...· 2 年前 ·

痴情的黄花菜 · javaScript DOM - 知乎· 2 年前 ·

淡定的蚂蚁 · GroupBox - WPF .NET ...· 2 年前 ·

威武的香菇 · javascript map 合并 ...· 3 年前 ·

Click on above to: Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension . Eur J Ophthalmol 2013; 23 : 47–54. [ PubMed ] [ Google Scholar ]

2. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly . Prog Retin Eye Res 2010; 29 : 312–334. doi: 10.1016/j.preteyeres.2010.03.001 [ PubMed ] [ Google Scholar ]

3. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug . Ophthalmology 1992; 99 : 1082–8. [ PubMed ] [ Google Scholar ]

4. Ciancaglini M, Carpineto P, Agnifili L, Nubile M, Fasanella V, Lanzini M, et al. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes . Eur J Ophthalmol 2008; 18 : 400–407. [ PubMed ] [ Google Scholar ]

5. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy . Surv Ophthalmol 2008; 53 ( Suppl 1 ): S93–105. [ PubMed ] [ Google Scholar ]

6. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review . Curr Opin Ophthalmol 2007; 18 : 134–139. [ PubMed ] [ Google Scholar ]

7. Noecker R. Effects of common ophthalmic preservatives on ocular health . Adv Ther 2001; 18 : 205–215. [ PubMed ] [ Google Scholar ]

8. Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology . Am J Ophthalmol 2009; 147 : 725–735. doi: 10.1016/j.ajo.2008.10.019 [ PubMed ] [ Google Scholar ]

9. Shin J, Lee JW, Choi BS, Yun EY, Jung JH, Kim EA, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma . J Ocul Pharmacol Ther 2014; 30 : 803–809. doi: 10.1089/jop.2014.0034 [ PubMed ] [ Google Scholar ]

10. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications . Cornea 2004; 23 : 490–496. [ PubMed ] [ Google Scholar ]

11. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost . Invest Ophthalmol Vis Sci 2007; 48 : 4123–4128. doi: 10.1167/iovs.07-0266 [ PubMed ] [ Google Scholar ]

12. Kim JH, Kim EJ, Kim YH, Kim YI, Lee SH, Jung JC, et al. In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study . Korean J Ophthalmol 2015; 29 : 270–279. doi: 10.3341/kjo.2015.29.4.270 [ PMC free article ] [ PubMed ] [ Google Scholar ]

13. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands . Cornea 2012; 31 : 1229–1234. [ PubMed ] [ Google Scholar ]

14. Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with Meibomian gland dysfunction . J Glaucoma 2016; 25 : 770–774. [ PubMed ] [ Google Scholar ]

15. Chawla A, McGalliard JN, Batterbury M. Use of eye drops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand 2007; 85 : 464 doi: 10.1111/j.1600-0420.2007.00882.x [ PubMed ] [ Google Scholar ]

16. Kekäle M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M. Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians . Patient Prefer Adherence 2014; 8 : 1619–1627. doi: 10.2147/PPA.S70712 [ PMC free article ] [ PubMed ] [ Google Scholar ]

17. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting . J Clin Hypretens (Greenwich) 2008; 10 : 348–354. [ PMC free article ] [ PubMed ] [ Google Scholar ]

18. de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra DP Jr. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults . Res Social Adm Pharm 2014; 10 : 554–561. doi: 10.1016/j.sapharm.2013.10.006 [ PubMed ] [ Google Scholar ]

19. Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: A cross sectional survey . Ophthalmology 2015; 122 : 1308–1316. doi: 10.1016/j.ophtha.2015.03.026 [ PMC free article ] [ PubMed ] [ Google Scholar ]

20. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension . Am J Manag Care 2009; 15 :59–66. [ PMC free article ] [ PubMed ] [ Google Scholar ]

21. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index . Arch Ophthalmol 2000; 118 : 615–621. [ PubMed ] [ Google Scholar ]

22. Yoon KC, Im SK, Kim HG, Yoo IC. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome . Cornea 2011; 30 : 972–976. [ PubMed ] [ Google Scholar ]

23. Yoon KC, Im SK, Park YG, Jung YD, Yang SY, Choi J. Application of umbilical cord serum eye drops for the treatment of dry eye syndrome . Cornea 2006; 25 : 268–272. doi: 10.1097/01.ico.0000183484.85636.b6 [ PubMed ] [ Google Scholar ]

24. Jung HH, Ji YS, Sung MS, Kim KK, Yoon KC. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjögren’s Syndrome . Chonnam Med J 2015; 51 : 26–32. doi: 10.4068/cmj.2015.51.1.26 [ PMC free article ] [ PubMed ] [ Google Scholar ]

25. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary . Invest Ophthalmol Vis Sci 2011; 52 : 1922–1929. doi: 10.1167/iovs.10-6997a [ PMC free article ] [ PubMed ] [ Google Scholar ]

26. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population . Ophthalmology 2008; 115 : 911–915. doi: 10.1016/j.ophtha.2007.06.031 [ PubMed ] [ Google Scholar ]

27. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome . Ophthalmology 1998; 105 : 1485–1488. doi: 10.1016/S0161-6420(98)98033-2 [ PubMed ] [ Google Scholar ]

28. Srinivasan S, Menzies K, Sorbara L, Jones L. Infrared imaging of meibomian gland structure using a novel keratograph . Optom Vis Sci 2012; 89 : 788–794. [ PubMed ] [ Google Scholar ]

29. Hong J, Sun X, Wei A, Cui X, Li Y, Qian T, et al. Assessment of tear film stability in dry eye with a newly developed keratograph . Cornea 2013; 32 : 716–721. [ PubMed ] [ Google Scholar ]

30. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial . Arch Ophthalmol . 2003; 121 : 48–56. [ PubMed ] [ Google Scholar ]

31. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial . Ophthalmology . 2007; 114 : 205–209. doi: 10.1016/j.ophtha.2006.07.060 [ PubMed ] [ Google Scholar ]

32. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma . Arch Ophthalmol . 2002; 120 : 701–713. [ PubMed ] [ Google Scholar ]

33. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma . Am J Ophthalmol . 1998; 126 : 498–505. [ PubMed ] [ Google Scholar ]

34. Ghosh S, O’Hare F, Lamoureux E, Vaipayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication . Clin Exp Ophthalmol 2012; 40 : 675–681. doi: 10.1111/j.1442-9071.2012.02781.x [ PubMed ] [ Google Scholar ]

35. Cvenkel B, Štunf Š, Srebotnik Kirbiš I, Strojan Fležar M. Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma . Clin Ophthalmol 2015; 8 : 625–631. [ PMC free article ] [ PubMed ] [ Google Scholar ]

36. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure lowering medications . Cornea 2010; 29 : 618–621. doi: 10.1097/ICO.0b013e3181c325b2 [ PubMed ] [ Google Scholar ]

37. Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma . Clin Ophthalmol 2012; 6 : 441–446. doi: 10.2147/OPTH.S29158 [ PMC free article ] [ PubMed ] [ Google Scholar ]

38. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucomatous drugs on the conjunctiva and Tenon’s capsule in glaucoma patients . Ophthalmology 1989; 96 : 327–335. [ PubMed ] [ Google Scholar ]

39. Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL. Conjunctival impression cytology in patients with glaucoma using long-term topical medication . Am J Ophthalmol 1991; 112 : 297–301. [ PubMed ] [ Google Scholar ]

40. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile . Arch Ophthalmol 1994; 112 : 1437–1445. [ PubMed ] [ Google Scholar ]

41. Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers . Br J Ophthalmol 1998; 82 : 39–42. [ PMC free article ] [ PubMed ] [ Google Scholar ]

42. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma . Ophthalmology 1994; 101 : 454–460. [ PubMed ] [ Google Scholar ]

43. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways . Ophthalmology 2008; 115 : 109–115. doi: 10.1016/j.ophtha.2007.01.036 [ PubMed ] [ Google Scholar ]

44. Jester JV, Nicolaides N, Smith R. Meibomian gland studies: histologic and ultrastructural investigations . Invest Ophthalmol Vis Sci 1981; 20 : 537–547. [ PubMed ] [ Google Scholar ]

45. Nicolaides N, Santos EC, Smith RE, Jester JV. Meibomian gland dysfunction, III: meibomian gland lipids . Invest Ophthalmol Vis Sci 1989; 30 : 946–951. [ PubMed ] [ Google Scholar ]

46. Foulks GN, Nichols KK, Bron AJ, Holland EJ, McDonald MB, Nelson JD. Improving awareness, identification, and management of meibomian gland dysfunction . Ophthalmology 2012; 119 : S1–12. doi: 10.1016/j.ophtha.2012.06.064 [ PubMed ] [ Google Scholar ]

47. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee . Invest Ophthalmol Vis Sci 2011; 52 : 1930–1937. doi: 10.1167/iovs.10-6997b [ PMC free article ] [ PubMed ] [ Google Scholar ]

48. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye . Ocul Surf 2004; 2 : 149–165. [ PubMed ] [ Google Scholar ]

49. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland . Invest Ophthalmol Vis Sci 2011; 52 : 1938–1978. doi: 10.1167/iovs.10-6997c [ PMC free article ] [ PubMed ] [ Google Scholar ]

50. Choi JH, Park JW, Park SW. The study of ocular side effects after the use of anti-glaucoma topical medication . J Korean Ophthalmol Soc 2013; 54 : 745–751. [ Google Scholar ]

51. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops . Clin Ophthalmol 2013; 7 : 2131–2135. doi: 10.2147/OPTH.S41358 [ PMC free article ] [ PubMed ] [ Google Scholar ]

52. Tsai JH, Derby E, Holland EJ, Khatana AK. Incidence and prevalence of glaucoma in severe ocular surface disease . Cornea 2006; 25 : 530–532. [ PubMed ] [ Google Scholar ]

53. De Saint JM, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells . Invest Ophthalmol Vis Sci

Making articles easier to read in PMC

Welcome to PubReader!